Latest News
Inhalon Biopharma to Share Progress in Advancing Inhaled Antibody Therapy Platform for Treating Respiratory Infections at BIO CEO & Investor Conference
​
CEO John Whelan to present recently published data and share development milestones
​
​Durham, North Carolina, February 10, 2025 — Inhalon Biopharma (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at the BIO CEO & Investor Forum being held February 10-11, 2025 in New York, N.Y. During his presentation on February 11, 2025, at 11 a.m. ET, Inhalon chief executive officer John Whelan will share an update on the company’s recently achieved development milestones, and newly published phase 1 data demonstrating the safety of its therapeutic platform, and its ability to reach and sustain therapeutic concentrations in the respiratory tract.
Inhalon Biophama is developing inhaled antibody products as potential treatments for a range of acute respiratory infections including respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza. This treatment approach involves the delivery of antibody therapy directly to the site of infection, using a handheld nebulizer rather than systemically via an oral or intravenous delivery. Inhaled treatment is believed to reduce costs and ease the burden of care on patients and the health care system.
“Vaccines developed to address respiratory infections, including influenza, RSV, and COVID-19 have not seen the uptake the public health community expected, while breakthrough infections have eroded trust in the immunization system writ large with dangerous public health consequences. As the U.S. fights the worst influenza season in 15 years, it’s clear that addressing the public health challenges posed by influenza and other respiratory infections is going to require new, more effective treatments that can be more easily administered in patient homes,” noted John Whelan, chief executive officer at Inhalon Biopharma. “The inhaled antibody therapeutic platform we’re developing is well-suited to address the challenges respiratory infections pose to public health and the healthcare system and can be easily adapted to address the threat of emerging respiratory pathogens.”
The company conducted phase 1 and phase 1b platform validating clinical trials on IN-006, an antibody against SARS-CoV-2 and recently announced plans to advance IN-002, its antibody treatment for RSV into a phase 2a study in 2026.
​
About Inhalon Biopharma
Inhalon Biopharma, Inc. is a private, clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Cambrian Growth Partners, Berkeley Catalyst Fund, JSR Life Sciences and Life Science Angels, as well as several federal grants from the NIH and USAMRDC.​
​
Contact
​
For General Inquires
John Whelan
Media
Gwen Gordon
​
​
​​